1.Regier, DA, Farmer, ME, Rae, DS, et al.Comorbidity of mental disorders with alchool and other drug abuse. JAMA. 1990;19:2511–2518.
2.Kessler, RC, McGonagle, KA, Zhao, S, et al.Lifetime and 12-month prevalence of DSM-IIIR psychiatric disorders in the United States:results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:8–19.
3.Kessler, RC, Nelson, CB, McGonagle, KA, Edlund, MJ, Frank, RG, Leaf, PJ. The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilization. Am J Orthopsychiatry. 1996;66:17–31.
4.Grant, BRHarford, TC. Comorbidity between DSM-IV alcohol use disorders and major depression: results of a national survey. Drug Alcohol Depend. 1995;39:197–206.
5.Merikangas, KR, Mehta, RL, Molnar, BE, et al.Comorbidity of substance use disorders with mood and anxiety disorders: results of the International Consortium in Psychiatric Epidemiology. Addict Behav. 1998;23:893–907.
6.Grant, BF, Stinson, FS, Dawson, DA, et al.Prevalence and co-occurrence of substance use disorders and Independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2004;61:807–816.
7.Swendsen, JD, Merikangas, KR. The comorbidity of depression and substance use disorders. Clin Psychol Rev. 2000;20:173–189.
8.Freed, EX. Alcohol abuse by manic patients. Psychol Rep. 1969;25:280.
9.Dunner, DL. Hensel, BM, Fieve, RR. Bipolar illness: factors in drinking behavior. Am J Psychiatry. 1979;136:583–585.
10.Hensel, B, Dunner, DL, Fieve, RR. The relationship of family history of alcoholism to primary affective disorder. J Affect Disord. 1979;1:105–113.
11.Estroff, TW, Dackls, CA, Gold, MS, Pottash, ALC. Drug abuse and bipolar disorders. Int J Psychiatry Med. 1985;15:37–40.
12.Bernardt, MW, Murray, RM. Psychiatric disorder, drinking and alcoholism: what are the links? Br J Psychiatry. 1986;148:393–400.
13.Miller, FT, Busch, F, Tanenbaum, JH. Drug abuse in schizophrenia and bipolar disorders. Am J Drug Alcohol Abuse. 1989;15:291–295.
14.Weiss, RD, Greenfield, SFNajavlts, LM, et al.Medication compliance among patients with bipolar disorder and substance use disorder. J Clin Psychiatry. 1998;59:172–174.
15.Goldberg, JF, Garno, JL, Leon, AC, Kocsis, JH, Portera, L. A history of substance abuse complicates remission from acute mania in bipolar disorder. J Clin Psychiatry. 1999;60:733–740.
16.Helzer, JE, Pryzbeck, TR. The co-occurrence of alcoholism with other psychiatric disorders in the general population and its Impact on treatment. J Stud Alcohol. 1988;49:219–224.
17.Mayfleld, DG, Coleman, LL. Alcohol use and affective disorder. Dis Nerv Syst. 1968;29:467–474.
18.Reich, LH, Davies, RK, Himmelhoch, JM. Excessive alcohol use in manic-depressive illness. Am J Psychiatry. 1974;131:83–86.
19.Winokur, G, Coryell, W, Endlcott, J, Keller, M, Akiskal, HS, Solomon, D. Familial alcoholism in manic-depressive (bipolar) disease. Am J Med Genet. 1996;67:197–201.
20.Mirin, SM, Weiss, R, Michael, J, Griffin, M. Psychopathology in substance abusers: Diagnosis and treatment. Am J Drug Alcohol Abuse. 1988;14:139–157.
21.Bisaga, A, Aharonovich, E, Garawi, Fet al.A randomized placebo-controlled trial of gabapentin for cocaine dependence. Drug Alcohol Depend. 2006;81:267–274.
22.Rounsaville, BJ, Weissman, MM, Rosenberger, PH, Wilbur, CH, Kleber, HD. Detecting depressive disorders in drug abusers: a comparison of screening Instruments. J Affect Disord. 1979;1:255–267.
23.Maremmani, I, Pacini, M, Pani, PRPerugi, G, Deltito, J, Akiskal, H. The Mental Status of 1090 Heroin Addicts at Entry into Treatment: Should Depression Be Considered a “Dual Diagnosis?” Ann Gen Psychiatry. 2007;6:31.
24.Sherwood Brown, E, Suppes, T, Adinoff, B, Ryan Thomas, N. Drug abuse and bipolar disorder: comorbidity or misdiagnosis? J Affect Disord. 2001;65:105–115.
25.Welch, SS, Linehan, MM. High-risk situations associated with parasulcide and drug use in borderline personality disorder. J Personal Disord. 2002;16:561–569.
26.Perugi, G, Frare, F.Madaro, D, Maremmani, I, Akiskal, HS. Alcohol abuse in social phobic patients: Is there a bipolar connection? J Affect Disord. 2002;68:33–39.
27.Maremmani, I, Perugi, G, Pacini, M, Akiskal, H. Toward a Unitary Perspective on the Bipolar Spectrum and Substance Abuse: Opiate Addiction as a Paradigm. J Affect Disord. 2006;93:1–12.
28.Goldberg, JF, Whiteside, JE. The association between substance abuse and antide-pressant-lnduced mania in bipolar disorder: a preliminary study. J Clin Psychiatry. 2002;63:791–795.
29.Bonson, KR, Murphy, DL. Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium. Behav Brain Res. 1996;73:229–233.
30.Tancer, M, Johanson, CE. The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacologyl (Berl). 2007;189:565–573.
31.van Harten, PN, van Trier, JC, Horwitz, EH, Matroos, GE, Hoek, HW. Cocaine as a risk factor for neuroleptic-induced acute dystonia. J Clin Psychiatry. 1998;59:128–130.
32.Johnson, BA, Rosenthal, N, Capece, JA, et al.Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA. 2007;298:1691–1692.
33.Winther, LC, Saleem, R, McCance-Katz, EF, et al.Effects of lamotrlglne on behavioral and cardiovascular responses to cocaine in human subjects. Am J Drug Alcohol Abuse. 2000;26:47–59.
34.Hirschowitz, J, Hitzemann, R, Kovasznay, B, et al.Lithium antagonism of ethanol-induced intoxication: relationship to Intracellular lithium levels. Psychiatry Res. 1989;29:55–63.
35.Judd, LL, Hubbard, RB, Huey, LY, Attewell, PA, Janowsky, DS, Takahashi, Kl. Lithium carbonate and ethanol Induced “highs” in normal subjects. Arch Gen Psychiatry. 1977;34:463–467.
36.Rush, CR, Pazzaglia, PJ. Pretreatment with isradlplne, a calcium-channel blocker, does not attenuate the acute behavioral effects of ethanol in humans. Alcohol Clin Exp Res. 1998;22:539–547.
37.Zacny, JPYajnlk, S. Effects of calcium channel inhibitors on ethanol effects and pharmacokinetics in healthy volunteers. Alcohol. 1993;10:505–509.
38.Leweke, FM, Emrich, HM. Carbamazepine as an adjunct in the treatment of schizophrenia-like psychosis related to cannabis abuse. Int Clin Psychopharmacol. 1999;14:37–39.
39.Haney, M, Hart, CL, Vosburg, SK, et al.Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology. 2004;29:158–170.
40.Ballard, CG, Mohan, RN, Handy, S. Carbamazeplne in alcohol withdrawal. Br J Psychiatry. 1991;158:133.
41.Bjorkqvlst, SE, Isohanni, M, Makela, R, Malinen, L. Ambulant treatment of alcohol withdrawal symptoms with carbamazeplne: a formal multicentre doubl-blind comparison with placebo. Acta Psychiatr Scand. 1976;53:333–342.
42.Chu, NS. Carbamazepine: prevention of alcohol withdrawal seizures. Neurology. 1979;29:1397–1401.
43.Butler, D, Messiha, FS. Alcohol withdrawal and carbamazepine. Alcohol. 1986;3:113–129.
44.Lemke, MR. (Differential diagnostic-therapeutic use of Carbamazepine in alcohol withdrawal syndrome]. Nervenarzt. 1995;66:77–79.
45. See S. Carbamazepine effective for alcohol withdrawal. J Fam Pract. 2002;51:778.
46.Agricola, R, Mazzarino, M, Urani, R, Gallo, V, Grossi, E. Treatment of acute alcohol withdrawal syndrome with carbamazepine: a double-blind comparison with tiapride. J Int Med Res. 1982;10:160–165.
47.Hillborn, M, Tokola, R, Kuusela, V, et al.Prevention of alcohol withdrawal seizures with carbamazepine and valproic acid. Alcohol. 1989;6:223–226.
48.Flygenring, J, Hansen, J, Holst, B, Petersen, E, Sorensen, A. Treatment of alcohol withdrawal symptoms in hospitalized patients. A randomized, double-blind comparison of carbamazepine (Tegretol) and barbital (Diemal). Acta Psychiatr Scand. 1984;69:398–408.
49.Malcolm, R, Ballenger, JC, Sturgls, ET, Anton, R. Double-blind controlled trial comparing carbamazeplne to oxazepam treatment of alcohol withdrawal. Am J Psychiatry. 1989;146:617–621.
50.Ritola, E, Malinen, L. A double-blind comparison of carbamazepine and clomethiazole in the treatment of alcohol withdrawal syndrome. Acta Psychiatr Scand. 1981,64:254–259.
51.Franz, M, Dlabal, H, Kunz, S, Ulferts, J, Gruppe, H, Gallhofer, B. Treatment of alcohol withdrawal: tiapride and carbamazepine versus clomethiazole. A pilot study. Eur Arch Psychiatry Clin Neurosci. 2001;251:185–192.
52.Lucht, M, Kuehn, KU, Armbruster, J, et al.Alcohol withdrawal treatment in Intoxicated vs non-Intoxicated patients: a controlled open-label study with tiapride/car-bamazepine, clomethiazole and diazepam. Alcohol Alcohol. 2003;38:168–175.
53.Soyka, M, Schmidt, P, Franz, M, et al.Treatment of alcohol withdrawal syndrome with a combination of tiapride/carbamazepine: results of a pooled analysis in 540 patients. Eur Arch Psychiatry Clin Neurosci. 2006;256:295–401.
54.Soyka, M. F. S., Schmidt, P. Efficacy and safety of outpatient alcohol detoxification with a combination of tiapride/carbamazepine: additional evidence. Pharmacopsychiatry. 2006;39:30–34.
55.Swantek, SS, Grossberg, GT, Neppe, VM, Doubek, WG, Martin, T, Bender, JE. The use of carbamazeplne to treat benzodiazepine withdrawal in a geriatric population. J Geriatr Psychiatry Neurol. 1991;4:106–109.
56.Ries, PK, Roy-Byrne, PPWard, NG, Neppe, V, Cullison, S. Carbamazepine treatment for benzodiazepine withdrawal. Am J Psychiatry. 1989;146:536–537.
57.Klein, E, Uhde, T, Post, RM. Preliminary evidence of the utility of carbamazepine in alprazolam withdrawal. Am J Psychiatry. 1986;143:235–236.
58.Schweizer, E, Rickeis, K, Case, WG, Greenblat, DJ. Carbamazepine treatment In patients discontinuing long-term benzodiazepine therapy: effects on withdrawal severity and outcome. Arch Gen Psychiatry. 1991;48:448–453.
59.Klein, E, Colin, V, Stolk, J, Lenox, RH. Alprazolam withdrawal in patients with panic disorder and generalized anxiety disorder: vulnerability and effect of carbamazeplne. Am J Psychiatry. 1994;151:1760–1766.
60.Kaendler, SH, Volk, S, Pflug, B. Benzodiazepine withdrawal and carbamazepine. Nervenarzt. 1996;67:381–386.
61.Schik, G, Wedegaertner, FR, Liersch, J, Hoy, L, Emrich, HM, Schneider, U. Oxcarbazepine vs carbamazeplne in the treatment of alcohol withdrawal. Addict Biol. 2005;10:283–288.
62.Croissant, B, Loeber, S, Diehl, A, et al.Oxcarbazepine in combination with Tiaprid in Inpatient alcohol-withdrawal-a RCT. Pharmacopsychiatry. 2009;42:175–181.
63.Rustembegovlc, A, Sofie, E, Kroyer, G. A pilot study of Toplramate (Topamax) in the treatment of tonic-clonlc seizures of alcohol withdrawal syndromes. Med Arh. 2002:56:211–212.
64.Krupitsky, EM, Rudenko, AA, Burakov, AM, et al.Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam. Alcohol Clin Exp Res. 2007;31:604–611.
65.Bonnet, U, Banger, M, Leweke, FM, Maschke, M, Kowalski, T, Gastpar, M. Treatment of alcohol withdrawal syndrome with gabapentin. Pharmacopsychiatry. 1999;32:107–109.
66.Bezikas, VPetrikis, RGamvrula, K, Sawidou, I, Karavatos, A. Treatment of alcohol withdrawal with gabapentin. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:197–199.
67.Voris, J, Smith, NL, Rao, SM, Thome, DL, Flowers, QJ. Gabapentin for the treatment of ethanol withdrawal. Subst Abus. 2003;24:129–132.
68.Mariani, JJ, Rosenthal, RN, Tross, S, Singh, RAnand, OP. A randomized, open-label, controlled trial of gabapentin and phenobarbital in the treatment of alcohol withdrawal. Am J Addict. 2006;15:76–84.
69.Bonnet, U, Banger, M, Leweke, FM, et al.Treatment of acute alcohol withdrawal with gabapentin: results from a controlled two-center trial. J Clin Pharmacol. 2003;23:14–19.
70.Malcolm, R, Myrick, LH, Veatch, LM, Boyle, E, Randall, PK. Self-reported sleep, sleepiness, and repeated alcohol withdrawals: a randomized, double blind, controlled comparison of lorazepam vs gabapentin. J Clin Sleep Med. 2007;3:24–32.
71.Karam-Hage, M, Brower, KJ. Open pilot study of gabapentin versus trazodone to treat insomnia in alcoholic outpatients. Psychiatry Clin Neurosci. 2003;57:542–544.
72.Brower, KJ, Myra Kim, H, Strobbe, S, Karam-Hage, MA, Consens, RZucker, RA. A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia. Alcohol Clin Exp Res. 2008;32:1429–1438.
73.Bonnet, U, Specka, M, Leweke, FM, Nyhuls, P, Banger, M. Gabapentin's acute effect on mood profile--a controlled study on patients with alcohol withdrawal. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:434–438.
74.Lambie, DG, Johnson, RH, Vijayasenan, ME, Whiteside, EA. Sodium valproate in the treatment of the alcohol withdrawal syndrome. Aust N Z J Psychiatry. 1980;14:213–215.
75.Reoux, JPSaxon, AJ, Malte, CA, Baer, JS, Sloan, KL. Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial. Alcohol Clin Exp Res. 2001;25:1324–1329.
76.Myrick, H, Brady, KT, Malcolm, R. Divalproex in the treatment of alcohol withdrawal. Am J Drug Alcohol Abuse. 2000;26:155–160.
77.Longo, LP, Campbell, T, Hubatch, S. Divalproex sodium (Depakote) for alcohol withdrawal and relapse prevention. J Addict Dis. 2002;21:55–64.
78.Rosenthal, RN, Perkel, C, Singh, P. Anand, O, Miner, CR. A pilot open randomized trial of valproate and phenobarbital in the treatment of acute alcohol withdrawal. Am J Addict. 1998;7:189–197.
79.Rickeis, K, Schweizer, E, Garcia, ERCase, G, DeMartinis, N, Greenblatt, D. Trazodone and valproate in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal symptoms and taper outcome. Psychopharmacology. 1999;141:1–5.
80.Banger, M, Benkert, O, Röschke, J, et al.Nimodipine in acute alcohol withdrawal state. J Psychiatr Res. 1992:26:117–123.
81.Altamura, AC, Regazzettl, MG, Porta, M. Nimodipine in human alcohol withdrawal syndrome--an open study. Eur Neuropsychopharmacol. 1990;1:37–40.
82.Gatti, A, Munari, L, Perretti, A, Porta, M, Altamura, C, Ragazzetti, MG. Sequential nlmodipine-reduced glutathione treatment in alcoholic abstinence syndrome. Preliminary experience. Minerva Med. 1992;83:277–281.
83.Krupitskii, EM, Burakov, AM, Priputina, LS, et al.[The efficacy of calcium channel blockers In the treatment of affective disorders and pathologic drive for alcohol in patients with alcoholism in the remission period]. Zh Nevrol Psikhiatr Im S S Korsakova. 2004;104:50–53.
84.Polycarpou, A, Papanikolaou, Rloannidis, JPContopoulos-loannidis, DG. Anticonvulsants for alcohol withdrawal. Cochrane Database Syst Rev. 2005;3:CD005064.
85.Jasinski, DR, Nutti, JG, Haertzen, CA, Griffith, JD. Lithium: Effects on subjective functioning and morphine-Induced euphoria. Science. 1977;195:582–584.
86.Bertschy, G, Bryois, C, Bondolfi, G, et al.The association carbamazepine-mianserin in opiate withdrawal: a double blind pilot study versus Clonidine. Pharmacological Research. 1997;35:451–456.
87.Eichelbaum, M, von Unruh, GE, Somogyi, A. Application of stable labelled drugs in clinical pharmacokinetic investigations. Clin Pharmacokinet. 1982;7:490–507.
88.Kumar, P, Jain, MK. Gabapentin in the management of pentazocine dependence: a potent analgesic-antlcraving agent. J Assoc Physicians India. 2003;51:673–676.
89.Martinez-Raga, J, Sabater, A, Perez-Galvez, B, Castellano, M, Cervera, G. Add-on gabapentin in the treatment of opiate withdrawal. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:599–601.
90.Freye, E, Levy, JV, Partecke, L. Use of gabapentin for attenuation of symptoms following rapid opiate detoxification (ROD)-correlation with neurophysiologlcal parameters. Neurophysiol Clin. 2004;34:81–89.
91.Kheirabadi, GR, Ranjkesh, M, Maracy, MR, Salehi, M. Effect of add-on gabapentin on opioid withdrawal symptoms in opium-dependent patients. Addiction. 2008;103:1495–1499.
92.Ignatov, ID, Andreev, BV. [Role of opioid and adrenergic mechanisms in the analgesic action of GABA-positlve drugs]. Biull Eksp Biol Med. 1988;105:556–558.
93.Tamayo, L, Contreras, E. A dual action of valproic acid upon morphine analgesia and morphine withdrawal. Pharmacology. 1983;26:297–302.
94.Saxon, AJ, Whittaker, S, Hawker, CS. Valproic acid, unlike other anticonvulsants has no effect on methadone metabolism: two cases. J Clin Psychiatry. 1989;50:228–229.
95.Jiménez-Lerma, JM, Landabaso, M, Iraurgi, L, Calle, R, Sanz, J, Gutiérrez-Fraile, M. Nimodipine in opiate detoxification: a controlled trial. Addiction. 2002;97:819–824.
96.Santillán, R, Hurlé, MA, Armijo, JA, de los Mozos, R, Flórez, J. Nimodipine-enhanced opiate analgesia in cancer patients requiring morphine dose escalation: a double-blind, placebo-controlled study. Pain. 1998;76:17–26.
97.Rosen, Ml, Pearsall, HR, Kosten, TR. The effect of lamotrigine on naloxone-precipl-tated opiate withdrawal. Drug Alcohol Depend. 1998;52:173–176.
98.Pani, PRAgus, A, Gessa, GL. Methadone as a mood stabilizer [Letter]. Heroin Addict Relat Clin Probl. 1999;1 (1):43–44.
99.Maremmani, I, Canoniero, S, Pacini, M. Methadone dose and retention in treatment of heroin addicts with Bipolar I Disorder comorbidity. Preliminary Results. Heroin Addict Belat Clin Probl. 2000;2:39–46.
100.Altamura, AC. Therapeutic attempts with lithium in young drug addicts. Acta Psychiatr Scand 1975;52:312–319.
101.Merry, J, Reynolds, C, Bailey, J, Coppen, A. Prophylactic treatment of alcoholism by lithium carbonate. A controlled study. Lancet. 1976;1:481–482.
102.Clark, DC, Fawcett, J. Does lithium carbonate therapy for alcoholism deter relapse drinking? Recent Dev Alcohol. 1989;7:315–328.
103.Fawcett, J, Clark, DC, Aagesen, CA, et al.A double-blind, placebo-controlled trial of lithium carbonate therapy for alcoholism. Arch Gen Psychiatry. 1987;44:248–256.
104.Fawcett, J, Clark, DC, Gibbons, RD, et al.Evaluation of lithium therapy for alcoholism. J Clin Psychiatry. 1984;45:494–499.
105.Pond, SM, Becker, CE, Vandervoort, R, Phillips, M, Bowler, RM, Peck, CC. An evaluation of the effects of lithium In the treatment of chronic alcoholism. I. Clinical results. Alcohol Clin Exp Res. 1981;5:247–251.
106.Powell, BJ, Penick, EC, Liskow, Bl, Rice, AS, McKnelly, W. Lithium compliance in alcoholic males: a six month followup study. Addict Behav. 1986;11:135–140.
107.Olbrich, R, Watzl, H, Volter, M, Siedow, H. Lithium in the treatment of chronic alcoholic patients with brain damage, a controlled study. Nervenarzt 1991;62:182–186.
108.Dorus, W, Ostrow, D, Anton, R, et al.Lithium treatment of depressed and nonde-pressed alcoholics. JAMA. 1989;262:1646–1652.
109.de la Fuente, JR, Morse, RM, Niven, RG, Ilstrup, DM. A controlled study of lithium carbonate in the treatment of alcoholism. Mayo Clin Proc. 1989;64:177–180.
110.Brady, KT, Sonne, SC, Malcolm, RJ, et al.Carbamazepine in the treatment of cocaine dependence: subtyping by affective disorder. Exp Clin Psychopharmacol. 2002;10:276–285.
111.Salloum, IM, Cornelius, JR, Daley, DC, Kirisci, L, Himmelhoch, JM, Thase, ME. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. Arch Gen Psychiatry. 2005;62:37–45.
112.Johnson, BA, Ait-Daoud, N, Bowden, CL, et al.Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003;361:1677–1685.
113.Fernandez Miranda, JJ, Marina Gonzàlez, PA, Montes Pérez, M, et al.Topiramate as add-on therapy in non-respondent alcohol dependant patients: a 12 month follow up study. Acta Esp Psiquiatr. 2007;35:236–242.
114.Croissant, B, Diehl, A, Klein, O, et al.A pilot study of oxcarbazepine versus acampro-sate in alcohol-dependent patients. Alcohol Clin Exp Res. 2006;30:630–635.
115.Martinotti, G, Di Nicola, M, Romanelli, R, et al.High and low dosage oxcarbazepine versus naltrexone for the prevention of relapse in alcohol-dependent patients. Hum Psychopharmacol. 2007;22:149–156.
116.Myrick, H, Anton, R, Voronin, K, Wang, W, Henderson, S. A double-blind evaluation of gabapentin on alcohol effects and drinking in a clinical laboratory paradigm. Alcohol Clin Exp Res. 2007;31:221–227.
117.Martinotti, G, Nicola, MD, Reina, D, et al.Alcohol protracted withdrawal syndrome: the role of anhedonia. Subst Use Misuse. 2008;43:271–284.
118.Nunes, EW, McGrath, PJ, Wager, S, Quitkin, FM. Lithium treatment for cocaine abusers with bipolar spectrum disorders. Am J Psychiatry. 1990;147:655–657.
119.Gawin, FH, Ellinwood, EH. Cocaine dependence. Ann Rev Med. 1989;40:149–161.
120.Gawin, FH, Kleber, HD. Cocaine abuse treatment: open pilot trial with desipramine and lithium carbonate. Arch Gen Psychiatry. 1984;41:903–909.
121.Campbell, JL, Thomas, HM, Gabrielli, W, Liskow, Bl, Powell, BJ. Impact of desipramine or carbamazepine on patient retention in outpatient cocaine treatment: preliminary findings. J Addict Dis. 1994;13:191–199.
122.Halikas, JA, Center, BA, Pearson, VL, Carlson, GA, Crea, F. A pilot, open clinical study of depakote in the treatment of cocaine abuse. Human Psychopharmacology. 2001;16:257–264.
123.Myrick, H, Henderson, S, Brady, K, Malcom, R, Measom, M. Divalproex loading in the treatment of cocaine dependence. J Psychoactive Drugs. 2001;33:283–287.
124.Reid, MS, Casadonte, P, Baker, S, et al.A placebo-controlled screening trial of olanzapine, valproate, and coenzyme Q10/L-carnitlne for the treatment of cocaine dependence. Addiction. 2005;100(S1):43–57.
125.Brown, ES, Nejtek, VA, Perantle, DC, Orsulak, PJ, Bobadilla, L. Lamotrigine in patients with bipolar disorder and cocaine dependence. J Clin Psychiatry. 2003;64:197–201.
126.Brown, ES, Perantie, DC, Dhanani, N, Beard, L, Orsulak, P, Rush, AJ. Lamotrigine for bipolar disorder and comorbid cocaine dependence: a replication and extension study. Addiction. 2006;93:219–222.
127.Berger, SP, Winhusen, TM, Somoza, EC, et al.A medication screening trial evaluation of reserpine, gabapentin and lamotrigine pharmacotherapy of cocaine dependence. Addiction. 2005;100(S1):58–67.
128.Margolin, A, Avants, SK, DePhilippis, D, Kosten, TR. A preliminary Investigation of lamotrigine for cocaine abuse in HIV-seroposltive patients. Am J Drug Alcohol Abuse. 1998;24:85–101.
129.Perretta, RAkiskal, HS, Nisita, C, et al.The high prevalence of bipolar II and associated cyclothymic and hyperthymic temperaments in HIV-patients. J Affect Disord. 1998;50:215–224.
130.Raby, W, Coomaraswamy, S. Gabapentin reduces cocaine use among addicts from a community clinic sample. J Clin Psychiatry. 2004;65:84–86.
131.Myrick, H, Henderson, S, Brady, K, Malcolm, R. Gabapentin in the treatment of cocaine dependence: a case series. J Clin Psychiatry. 2001;62:19–23.
132.Haney, M, Hart, C, Collins, ED, Foltin, RW. Smoked cocaine discrimination in humans: effects of gabapentin. Drug Alcohol Depend. 2005;80:53–61.
133.Hart, CL, Haney, M, Vosburg, SK, Rubin, E, Foltin, RW. Gabapentin does not reduce smoked cocaine self-administration: employment of a novel self-administration procedure. Behav Pharmacol. 2007;18:71–75.
134.Gonzalez, G, Desaj, R, Sofuoglu, M, et al.Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone-treated patients. Drug Alcohol Depend. 2007;87:1–9.
135.Hart, CL, Haney, M, Collins, ED, Rubin, E, Foltin, RW. Smoked cocaine self-admlnls-tration by humans is not reduced by large gabapentin maintenance doses. Drug Alcohol Depend. 2007;86:274–277.
136.Sharpe, LG, Jaffe, JH, Katz, JL. Carbamazepine produces nonspecific effects on cocaine self-administration in rats. Life Sci. 1992;51:13–18.
137.Carroll, ME, Lac, ST, Asencio, M, Halikas, JA, Kragh, R. Effects of carbamazeplne on self-administration of intravenously delivered cocaine in rats. Pharmacol Biochem Behav. 1990;37:551–556.
138.Baptista, T, Weiss, SR, Post, RM. Carbamazepine attenuates cocaine-induced increases in dopamine in the nucleus accumbens: an in vivo dialysis study. Eur J Pharmacol. 1993;236:39–42.
139.Hatsukami, D, Keenan, R, Halikas, J, Pentel, PR, Brauer, LH. Effects of carbamazeplne on acute responses to smoked cocaine-base in human cocaine users. Psychopharmacology. 1991;104:120–124.
140.Halikas, JA, Crosby, RD, Pearson, VL, Graves, NM. A randomized double-blind study of carbamazepine in the treatment of cocaine abuse. Clin Pharmacol Ther. 1997;62:89–105.
141.Halikas, JA, Crosby, RD, Carlson, GA, Crea, RGraves, NM, Bowers, LD. Cocaine reduction in unmotivated crack users using carbamazepine versus placebo in a short-term, double-blind crossover design. Clin Pharmacol Ther. 1991;50:81–95.
142.Montoya, ID, Levin, FR, Fudala, PJ, et al.Double-blind comparison of carbamazepine and placebo for treatment of cocaine dependence. Drug Alcohol Depend. 1995;38:213–219.
143.Kranzler, HR, Bauer, LO, Hersh, D, Klinghoffer, V. Carbamazepine treatment of cocaine dependence: a placebo-controlled trial. Drug Alcohol Depend. 1995;38:203–211.
144.Lima, AR, Lima, MS, Soares, BG, Farrell, M. Carbamazepine for cocaine dependence. Cochrane Database Syst Rev. 2002;2:CD002023.
145.Kuhn, KL, Halikas, JA, Kemp, KD. Carbamazeplne treatment of cocaine dependence in methadone maintenance patients with dual opiate-cocaine addiction. NIDA Res Monogr. 1989;95:316–317.
146.Halikas, JA, Kuhn, KL, Crea, FS, Carlson, GA, Crosby, R. Treatment of crack cocaine use with carbamazepine. Am J Drug Alcohol Abuse. 1992;18:45–56.
147.Llopis Llacer, JJ, Castillo Aguilella, A. [Efficacy of oxcarbazepine treatment in patients diagnosed with cocaine abuse/dependence]. Adicciones. 2008;20:263–270.
148.Minozzi, S, Amato, L, Davoli, M, et al.Anticonvulsants for cocaine dependence. Cochrane Database Syst Rev. 2008;2:CD006754.
149.Nagel, K, Adler, L, Bell, J, Nagamoto, H, Freedman, R. Lithium carbonate and mood disorder in recently detoxified alcoholics: a double-blind, placebo-controlled pilot study. Alcohol Clin Exp Res. 1991; 15:978–981.
150.Weiss, RD, Mirin, SM, Tricyclic antidepressants in the treatment of alcoholism and drug abuse. J Clin Psychiatry. 1989;50(Suppl:4-9); discussion 9–11.
151.Albanese, MJ, Clodfelter, RCJ, Khantzlan, EJ. Divalproex sodium in substance abusers with mood disorder. J Clin Psychiatry. 2000;61:916–921.
152.Brady, KT, Sonne, SC, Anton, R, Ballenger, JC. Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study. J Clin Psychiatry. 1995;56:118–121.
153.Hertzman, M. Divalproex sodium to treat concomitant substance abuse and mood disorders. Subst Abuse Treat. 2000;18:371–372.
154.Roberts, JM, Malcolm, R, Santos, AB. Treatment of panic disorder and comorbid substance abuse with divalproex sodium. Am J Psychiatry. 1994;151:1521.
155.Campbell, J, Nickel, EJ, Penick, EC, et al.Comparison of desipramine or carbamazepine to placebo for crack cocaine-dependent patients. Am J Addict 2003;12:122–136.
156.Ballenger, JC, Post, RM. Carbamazepine in alcohol withdrawal syndromes and schizophrenic psychoses. Psychopharmacol Bull. 1984;20:572–584.
157.Hernandez-Avila, CA, Ortega-Soto, HA, Jasso, A, Hasfura-Buenaga, CA, Kranzler, HR. Treatment of inhalant-induced psychotic disorder with carmabazepine verus haloperidol. Psychiatr Serv. 1998;49:812–815.
158.Camacho, A, Akiskal, HS. Proposal for a bipolar-stimulant spectrum: temperament, diagnostic validation and therapeutic outcomes with mood stabilizers. J Affect Disord. 2005;85:217–230.
159.Keck, PEJ, McElroy, SL, Friedman, LM. Valproate and carbamazepine in the treatment of panic and posttraumatic stress disorders, withdrawal states, and behavioral dyscontrol syndromes. J Clin Pharmacol. 1992:(1 suppl):36s–41s.
160.Skinstad, AH, Swain, A. Comorbidity in a clinical sample of substance abusers. Am J Drug Alcohol Abuse. 2001;27(1):45–64.